Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review
- 28 July 2020
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14097
Abstract
Pityriasis rubra pilaris (PRP) is a rare heterogeneous group of papulosquamous inflammatory disorders with unknown etiology. PRP is often resistant to many conventional therapies which has made more challenging on treatment. More recently, several studies have shown encouraging clinical results of secukinumab in the treatment of PRP in adult, but no studies have explored its effects in children. We herein report a 7‐year‐old boy with severe type V PRP responded rapidly to secukinumab monotherapy (150 mg once weekly) when conventional therapies have failed. The patient showed rapid and dramatic improvement of erythema, palmoplantar hyperkeratosis, scaling and itching within only 5 weeks, with no adverse effects. Secukinumab could be considered as a treatment option for refractory PRP in children, as recently reported in adult.Keywords
This publication has 13 references indexed in Scilit:
- Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin‐17A, but improved after blockade of interleukin‐12/23 p40The Journal of Dermatology, 2018
- Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasetsJAAD Case Reports, 2018
- A Review on Pityriasis Rubra PilarisAmerican Journal of Clinical Dermatology, 2018
- Resolving classic pityriasis rubra pilaris, mimicker of erythema gyratum repensAustralasian Journal of Dermatology, 2017
- Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 MutationsJAMA Dermatology, 2017
- Successful treatment of type II pityriasis rubra pilaris with secukinumabJAAD Case Reports, 2016
- Successful Treatment of Refractory Pityriasis Rubra Pilaris With SecukinumabJAMA Dermatology, 2016
- Response of persistent juvenile pityriasis rubra pilaris to secukinumabJournal of the American Academy of Dermatology, 2016
- Alitretinoin (9-cis Retinoic Acid) is Effective Against Pityriasis Rubra Pilaris: A Retrospective Clinical StudyActa Dermato-Venereologica, 2015
- Original article Pityriasis rubra pilaris-an historical approach. 2 CLINICAL FEATURESClinical and Experimental Dermatology, 1976